KeyToFinancialTrends notes that in recent weeks, the market has been shaken by rumors about a possible acquisition of Abivax by the large pharmaceutical company Eli Lilly. Speculation about a potential deal led to a sharp rise in Abivax’s stock price, attracting the attention of investors and analysts. However, Abivax’s CEO, Marc de Garidel, quickly denied these rumors, stating that there was no basis for them. At the center of attention is the company’s drug, obefazimod, which has shown positive results in the final stage of clinical trials. This development could be key to Abivax’s long-term success.
The surge in Abivax’s stock, which increased by over 2000% from July to December 2025, was undoubtedly linked to the successes in the clinical trials of obefazimod, a drug intended to treat inflammatory bowel diseases. However, in December, rumors began circulating that Eli Lilly was negotiating with French authorities regarding the potential acquisition of Abivax. These reports led to a sharp rise in Abivax’s stock price, which reached 145 euros per share, but after denials from the company and the French government, the stock returned to 101 euros. The rumors quickly dissipated, but they brought attention to the company as a potential acquisition target.
Marc de Garidel, the CEO of Abivax, emphasized that he had no knowledge of any meetings with Eli Lilly or other major pharmaceutical companies discussing an acquisition. Moreover, according to him, such negotiations would violate French laws regulating foreign investments and would have had to be publicly announced, which did not happen. This statement confirms that, at present, Abivax remains an independent company focused on developing its scientific projects rather than seeking a sale.
At KeyToFinancialTrends, we believe it’s important to distinguish market rumors from real opportunities for the company. Abivax continues to demonstrate strong scientific potential, and the successes in the development of obefazimod open new horizons for the company. This drug, aimed at the rapidly growing market for treating inflammatory bowel diseases, could become an important asset that attracts the attention of large pharmaceutical companies, even if it is not subject to acquisition.
Furthermore, it’s important to note that despite the need to raise additional capital to reach profitability, Abivax has sufficient financial resources to carry out its projects until 2027. With growing interest in the company’s developments and successful clinical trial results, Abivax has opportunities for strategic partnerships with other major players. We at KeyToFinancialTrends emphasize that such partnerships could be beneficial both for Abivax and for large pharmaceutical companies, such as Eli Lilly, interested in expanding their portfolio of innovative drugs.
As for the next steps, we at KeyToFinancialTrends predict that the success of obefazimod in the third phase of clinical trials could significantly increase Abivax’s market value and strengthen its position in the pharmaceutical sector. This drug has the potential to become one of the leading solutions in the inflammatory bowel disease market, bolstering Abivax’s reputation as a developer of high-quality biopharmaceutical products.
In conclusion, despite the speculation, Abivax continues to strengthen its position in research and commercial activities. The company remains focused on executing its ambitious plans and finding paths for long-term growth. We at Key To Financial Trends see significant potential in this for future investors. Should obefazimod succeed, Abivax could become an important player in the international market, opening new opportunities for growth and strategic partnerships.
